We have launched our latest MES version: PAS-X MES 3.3 Suite, the market-leading NextGen MES for pharma, biotech and cell & gene, bringing together over 30 years of expert domain knowledge with leading IT technologies to provide a GMP-ready product that is built for the future of the industry.
Best practice: Novo Nordisk leads cloud-native manufacturing with NextGen PAS-X MES
Driven to deliver medicines to patients faster with more agility, Novo Nordisk is leading the pharma industry’s technology advancement by bringing MES to the cloud through their strategic partnership with Körber. Körber’s PAS-X MES 3.3 Suite will be deployed in Novo Nordisk’s private Azure cloud infrastructure to implement MES faster than ever.
As an early adopter, Novo Nordisk and Körber are working closely on the development and deployment of PAS-X MES 3.3 to ensure the success of this cutting-edge program. So far, this close partnership has enabled PAS-X MES to be on a massive scale already.
With PAS-X MES 3.3 at the center of Novo Nordisk’s Pharma 4.0 digital ecosystem, the company will be able to bring best-of-breed applications with out-of-the-box capabilities tailored to GMP production to manufacturing sites across the world – globally empowering workforces and increasing manufacturing productivity.
Körber has developed PAS-X MES 3.3 as a solution that will continue to evolve with market needs through a continuous evolution stream support model that will allow Novo Nordisk to continuously bring new functionality into production.